OPUS GENETICS INC. - COMMON STOCK

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

08 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and Progress

07 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Opus Genetics to Participate in Upcoming Investor Conference in April

02 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Opus Genetics Announces Financial Results for Full Year 2024

31 Mar 2025 08:20:26 By Nasdaq GlobeNewswire

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

21 Mar 2025 09:30:23 By Nasdaq GlobeNewswire

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

21 Mar 2025 09:11:48 By Nasdaq GlobeNewswire

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Mar 2025 15:56:18 By Nasdaq GlobeNewswire

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

05 Mar 2025 08:00:32 By Nasdaq GlobeNewswire

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

26 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

18 Feb 2025 07:30:02 By Nasdaq GlobeNewswire

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

19 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

03 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update

12 Nov 2024 08:00:02 By Nasdaq GlobeNewswire

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 Nov 2024 07:59:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Acquisition of Opus Genetics

22 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

05 Sep 2024 20:43:59 By Nasdaq GlobeNewswire

Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

05 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

13 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at Two Investor Conferences in August

08 Aug 2024 08:00:00 By Nasdaq GlobeNewswire